FDA
-
-
-
-
-
-
-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Compass Pathways study finds COMP360 support differs from psychotherapy
-
-
-
-
-
-
-
Jefferies on Compass Pathways (CMPS): 'We remain 75-85%+ confident the FDA approves COMP360 (oral psilocybin) around YE:26/early 2027'
-
-
-
-
-
-
-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Wolfe Research Starts Compass Pathways (CMPS) at Outperform
-
-
-
-
-
-
-
Jefferies Starts Compass Pathways (CMPS) at Buy
-
-
-
-
-
-
-
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
-
329,914 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

